Psyence Biomedical cash flow statement data for the quarter ended Mar 2026. This cash flow statement covers 6 quarters of results from Sep 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Sep2022 | Mar2023 | Sep2023 | Sep2024 | Sep2025 | Mar2026 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 0.01B | -3206.40B | 0.00B | 0.00B | -0.00B | |
| Depreciation and Depletion | 0.00B | 0.00B | ||||
| Share-based Compensation | 221.29B | 0.00B | ||||
| Gains from Investment Securities | -0.01B | -0.00B | 0.00B | -0.00B | ||
| Cash from Operations | -0.00B | -1592.08B | -0.00B | |||
| Depreciation, Depletion & Amortization | ||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.00B | 0.00B | ||||
| Change in Working Capital | ||||||
| Change in Account Payables | 0.00B | -0.00B | ||||
| Change in Accured Expenses | 0.00B | 1,670.95B | 0.00B | |||
| Other Working Capital Changes | 0.00B | -71.67B | 0.00B | |||
| Investing Activities | ||||||
| Cash from Investing Activities | 0.25B | |||||
| Financing Activities | ||||||
| Debt Issuance and Repayment | ||||||
| Long-Term Debt Issuances | 0.00B | |||||
| Change in Capital Stock | ||||||
| Net Equity Issued and Repurchased | -0.25B | |||||
| Misc. | ||||||
| Cash from Financing Activities | 1,172.92B | -0.25B | ||||
| Exchange Rate Effect | -84.50B | |||||
| Change in Cash | -0.00B | -419.16B | -0.00B | |||
| Beginning Cash Balance | 0.00B | 0.00B | 0.00B | 0.01B | ||
| Free Cash Flow | -0.00B | -1432.85B | -0.00B | |||
| Net Cash Flow | -0.00B | -285.03B | -0.00B |